• Alias: FZD8-Fc
    • First-in-class recombinant fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (FZD8) fused to the human immunoglobulin Fc domain that competes with the membrane-bound FZD8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling, resulting in the inhibition of Wnt-driven tumor growth
    • Currently in phase 1 clinical trials for solid tumors in combination with chemotherapy
    • Recommended dose: 2.5 to 10 mg/kg IV every 3 weeks
    • Half-life: 4 days
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Nausea/vomiting, anorexia, fatigue, dysgeusia, hypertension, hypocalcemia, peripheral edema
    (Smith    al., 2013)
    Other topics in Targeted and Immunotherapy Agents